Nektar Therapeutics Files Prospectus for Public Offering to Support Drug Development Initiatives

Reuters
10 hours ago
Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Files Prospectus for Public Offering to Support Drug Development Initiatives

Nektar Therapeutics, a clinical-stage biotechnology company specializing in immunotherapy, has announced the filing of a preliminary prospectus supplement with the U.S. Securities and Exchange Commission $(SEC.UK)$ as part of its proposed underwritten public offering. The company plans to offer shares of its common stock and pre-funded warrants to certain investors. Jefferies and Piper Sandler are acting as joint bookrunning managers for the offering. The proceeds are intended for general corporate purposes, including research, development, and manufacturing costs for advancing drug candidates. The offering is subject to market conditions, and Nektar has granted underwriters a 30-day option to purchase an additional 15% of the shares. The offering is made under a shelf registration statement declared effective on April 1, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF21403) on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10